Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 6:16:115-124.
doi: 10.2147/LCTT.S511767. eCollection 2025.

Emerging Targets in Non-Small Cell Lung Cancer

Jing Wang  1 , Layana Biglow  1 , Megan Baumgart  1
Affiliations
Review

Emerging Targets in Non-Small Cell Lung Cancer

Jing Wang et al. Lung Cancer (Auckl). .

Abstract

The identification of molecular driver mutations in non-small cell lung cancer (NSCLC) has changed the therapeutic landscape for this disease. Over the last 20 years, a growing number of driver mutations have been identified in addition to new targeted therapies that have resulted in significant improvement in survival for a subset of patients. There is ongoing research to identify additional molecular targets and therapeutic strategies to improve outcomes in a greater percentage of patients with lung cancer. This review aims to highlight new therapeutic strategies targeting known driver mutations and data regarding emerging molecular targets for the treatment of NSCLC.

Keywords: driver mutations; molecular alterations; non-small cell lung cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834 - DOI - PubMed
    1. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001. doi: 10.1200/JCO.2012.46.9270 - DOI - PubMed
    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. doi: 10.3322/caac.21820 - DOI - PubMed
    1. Abughanimeh O, Kaur A, El Osta B, Ganti AK. Novel targeted therapies for advanced non-small lung cancer. Semin Oncol. 2022;49(3–4):326–336. - PubMed
    1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550. doi: 10.1038/nature13385 - DOI - PMC - PubMed

LinkOut - more resources